HYPERFINE INC

Hyperfine Inc. (HYPR, CUSIP 44916K106) entered Q1 2026 with only $20M in institutional 13F value across 51 holders — a figure and concentration level appropriate for a speculative small-cap medtech whose technology represents genuine product innovation but whose revenue scale has not yet crossed the threshold that would draw institutional coverage. The signal worth surfacing: five new positions were opened or meaningfully expanded in Q1 against a tiny holder base, including interest from Renaissance Technologies LLC, a quantitatively-focused manager whose involvement is a documented indicator of asymmetric upside attention rather than broad institutional consensus. The 51-holder concentration is a function of both stage and market-cap: Hyperfine's portable MRI technology (Swoop system — low-field, bedside MRI) addresses a real clinical need in emergency and resource-limited settings, and institutional interest at this stage is concentrated among specialist healthcare and biotech-conviction managers, not diversified healthcare mandates. For smart-money trackers, HYPR is a concentrated conviction-bet quality: the holder count is tiny, but the presence of a quantitative-alpha manager like Renaissance as a positioned holder raises the posterity risk of this name.